RLMDNasdaqPharmaceutical PreparationsFiscal year ends December 31
RELMADA THERAPEUTICS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$3.16+0.06 (+1.94%)
Close on Oct 19, 2026
- Market cap
- $355.11M
- P/E (TTM)
- –
- Dividend yield
- –
Relmada Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Relmada Therapeutics | Industry median |
|---|---|---|
| Market Cap | $337.08M | $166.30M |
| Enterprise Value | $119.35M | $88.19M |
| PB Ratio | 1.63 | 2.03 |
| P/TBV Ratio | 1.63 | 2.29 |
Income (trailing twelve months)
| Measure | Relmada Therapeutics | Industry median |
|---|---|---|
| Operating Income | -$65.13M | -$21.40M |
| Net Income | -$61.93M | -$22.46M |
| EBITDA | -$65.13M | -$16.91M |
| EPS (Diluted) | -$0.96 | -$0.83 |
Returns
| Measure | Relmada Therapeutics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -55.7% | -53.2% |
| Return on Assets (ROA) | -51.6% | -40.9% |
| Return on Capital Employed (ROCE) | -30.8% | -38.1% |
Balance sheet
| Measure | Relmada Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $217.73M | $61.43M |
| Net Cash (Debt) | $217.73M | $15.35M |
| Net Cash Per Share | $2.04 | $0.66 |
| Equity (Book Value) | $206.56M | $49.09M |
| Book Value Per Share | $1.94 | $1.37 |
| Tangible Book Value | $206.56M | $23.52M |
| Working Capital | $211.62M | $76.81M |
Financial position
| Measure | Relmada Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 29.52 | 3.34 |
| Quick Ratio | 29.34 | 2.44 |
Cash flow (trailing twelve months)
| Measure | Relmada Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$45.99M | -$12.35M |
Efficiency
| Measure | Relmada Therapeutics | Industry median |
|---|---|---|
| Profits Per Employee | -$3.64M | -$703.34K |
| Employee Count | 17 | 74 |
Dividends and yields
| Measure | Relmada Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -18.4% | -23.3% |
Shares
| Measure | Relmada Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 106,670,000 | 58,127,000 |
| Shares Change (YoY) | 136.6% | 10.9% |
| Shares Change (QoQ) | 1.70% | 0.54% |
| Float | 103,179,000 | 49,136,700 |
| Shares Held by Insiders | 3.27% | 11.6% |
| Shares Held by Institutions | 94.0% | 59.4% |
Scores
| Measure | Relmada Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | 11.69 | -0.22 |
| Piotroski F-Score | 4 | 4 |
Calculated by StockData from Relmada Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.